Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,170.45 +42.66 (+0.83%) Dow
38,785.36 +109.68 (+0.28%) Nasdaq
16,315.98 +159.66 (+0.99%) Bitcoin USD
63,087.16 -799.95 (-1.25%) CMC Crypto 200
1,357.14 +44.52 (+3.39%)
MGNX Oct 2024 25.000 call
| Previous close | 4.6000 |
| Open | 4.6000 |
| Bid | 2.0500 |
| Ask | 3.4000 |
| Strike | 25.00 |
| Expiry date | 2024-10-18 |
| Day's range | 4.6000 - 4.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
GlobeNewswireMacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, M
Simply Wall St.We're Hopeful That MacroGenics (NASDAQ:MGNX) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, MacroGenics ( NASDAQ:MGNX...
- GlobeNewswire
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data, including safety and preliminary efficacy, by May 31Company plans to provide additional clinical data – including rPFS – in the Fall of 2024 ROCKVILLE, MD, April 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing
